XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 3,745 $ 4,024 $ 7,285 $ 7,951  
Selling, general and administrative 2,739 2,702 5,221 5,182  
Research and development 3,500 13,321 7,492 17,597  
Other current assets 38,205   38,205   $ 32,168
Accrued and other current liabilities 14,712   14,712   15,766
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 354 335 684 633  
Cost of sales 82 78 163 148  
Selling, general and administrative 43 51 82 98  
Research and development 18 22 38 43  
Other current assets 349   349   341
Accrued and other current liabilities 615   615   256
Other noncurrent liabilities 0   0   $ 600
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 317 310 609 585  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement $ 37 $ 25 $ 75 $ 48